184
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D

, , , &
Pages 667-675 | Received 17 Apr 2018, Accepted 24 Jul 2018, Published online: 03 Aug 2018

References

  • GBD 2015. Disease and injury incidence and prevalence, collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.
  • Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478.
  • Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178.
  • Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99.
  • Stamatopoulou Ε, Stamatopoulou A, Brinia A, et al. Good practices investigating bronchial asthma as psychosomatic disease. Prim Care Respir Update. 2017;4:63.
  • Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
  • Schermer T, Thoonem B, Van den Boom G, et al. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med. 2002;166:1062–1072.
  • Stahl E, Postma DS, Svensson K, et al. Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir Med. 2003;97:1061–1066.
  • Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics. 2004;22:537–547.
  • NICE. NICE’s position statement on EQ-5D-5L. London: National Institute for Health and Care Excellence. 2017.
  • Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE Health Technology Assessments. Value Health. 2013;16:202–210.
  • Hawthorne G, Richardson J, Na D. A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Ann Med. 2001;33:358–370.
  • Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol. 2003;56:317–325.
  • Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873–884.
  • Szende A, Leidy NK, Stahl E, et al. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res. 2009;18:267–272.
  • Ferreira LN, Ferreira PL, Pereira LN. Comparing the performance of the SF-6D and the EQ-5D in different patient groups. Acta Med Port. 2014;27:236–245.
  • Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061–1067.
  • Kontodimopoulos N, Argiriou M, Theakos N, et al. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. Eur J Health Econ. 2011;12:383–391.
  • Kontodimopoulos N, Pappa E, Chadjiapostolou Z, et al. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications. Eur J Health Econ. 2012;13:111–120.
  • Kontodimopoulos N, Pappa E, Papadopoulos AA, et al. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res. 2009;18:87–97.
  • Herdman M, Nazir J, Hakimi Z, et al. Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial. Patient. 2017;10:677–686.
  • Pickard SA, Gooderham M, Hartz S, et al. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017;20(19–27).
  • Sullivan PW, Ghushchyan VH, Campbell JD, et al. Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes. Qual Life Res. 2016;25:3017–3026.
  • Brazier JE, Deverill M, Harper R, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3:1–164.
  • Guyatt GH, King DR, Feeny DH, et al. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52:187–192.
  • Young T, Yang Y, Brazier JE, et al. The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res. 2009;18:253–265.
  • Young TA, Yang Y, Brazier JE, et al. The use of Rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making. 2011;31:195–210.
  • Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Med Decis Making. 2011;31:281–291.
  • McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008;17:453–462.
  • Swinburn P, Lloyd A, Boye KS, et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013;16:1156–1162.
  • Krahn M, Bremner KE, Tomlinson G, et al. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2007;16:509–522.
  • Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
  • Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
  • Kontodimopoulos N, Pappa E, Niakas D, et al. Validity of the EQ-5D instrument in a Greek general population. Value Health. 2008;11:1162–1169.
  • Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292.
  • Pappa E, Kontodimopoulos N, Niakas D. Validating and norming of the Greek SF-36 Health Survey. Qual Life Res. 2005;14:1433–1438.
  • Juniper EF, Buist A, Cox F, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265–1270.
  • Juniper EF, Guyatt GH, Ferrie P, et al. Measuring quality of life in asthma. Am J Respir Dis. 1993;147:832–838.
  • Grammatopoulou E, Skordilis E, Koutsouki D, et al. An 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S). Qual Life Res. 2008;17:323–332.
  • Juniper EF, O’Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway caliber and rescue beta2-agonist use? Respir Med. 2001;95:319–323.
  • Global initiative for asthma (GINA) guidelines. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report (1998).
  • Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–907.
  • Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415.
  • Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.
  • Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–749.
  • Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 1995;60:1571–1582.
  • Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–1532.
  • Wyrwich KW, Khan SA, Navaratnam P, et al. Validation and agreement across four versions of the asthma control questionnaire in patients with persistent asthma. Respir Med. 2011;105:698–712.
  • Cohen J. Statistical power analysis for the behavioral sciences. New Jersey, USA: Routledge; 1977.
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307–310.
  • Nunnaly JC, Bernstein IR. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
  • Räsänen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006;22:235–241.
  • Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13–35.
  • Lamers L, Bouwmans C, van Straten A, et al. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006;15:1229–1236.
  • Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ. 2009;10:15–23.
  • Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002;11:447–456.
  • Finch A, Brazier J, Mukuria C. What is the evidence for the performance of generic preference based measures? A systematic overview of reviews. Eur J Health Econ. 2017;30:1–14.
  • Ferreira PL, Ferreira LN, Pereira LN. How consistent are health utility values? Qual Life Res. 2008;17:1031–1042.
  • Juniper EF, Bousquet J, Abetz L, et al. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med. 2006;100:616–621.
  • Sadatsafavi M, McTaggart-Cowan H, Chen W, et al. Economic burden of asthma (EBA) study group. Quality of Life and Asthma Symptom Control: room for Improvement in Care and Measurement. Value Health. 2015;18:1043–1049.
  • Zannetos S, Zachariadou T, Zachariades A, et al. The economic burden of adult asthma in Cyprus: a prevalence-based cost of illness study. BMC Public Health. 2017;17:262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.